London | December 2025
GlaxoSmithKline (GSK) today highlighted a defining reflection from its outgoing Chief Executive Officer, Dame Emma Walmsley, who described the success of GSK’s medicines as “the best feeling” of her tenure, underscoring the human and scientific impact at the heart of the company’s mission.
As she prepares to step down, Dame Emma shared that the moment she will miss most is receiving the long-awaited results of clinical trials—a pivotal milestone that represents years of scientific dedication, patient participation, and investment.
“There is nothing quite like the moment when you see the results of a clinical trial and know that a medicine can genuinely change lives,” Dame Emma said. “That feeling—when science delivers for patients—is the reason we do what we do.”
A Decade Focused on Science and Patients
Under Dame Emma’s leadership, GSK sharpened its strategic focus on vaccines, specialty medicines, and infectious diseases, reinforcing its commitment to science-led innovation. Her tenure saw:
- Strengthened R&D productivity with a more disciplined, pipeline-driven approach
- Multiple new medicine and vaccine approvals across key therapeutic areas
- Increased emphasis on patient-centric development and global access to medicines
Clinical trial milestones became central moments at GSK—reflecting not only scientific success, but also hope for patients waiting for new treatment options.
The Emotional Core of Drug Development
Dame Emma emphasized that beyond financial performance or market share, the emotional impact of successful trials defined her leadership journey.
“Behind every data point is a patient, a family, and a future that could be different,” she noted. “That responsibility is humbling, and the reward of success is incomparable.”
Looking Ahead
As GSK transitions to its next phase of leadership, the company reaffirmed its commitment to advancing transformative medicines and vaccines, building on the scientific foundations strengthened during Dame Emma Walmsley’s tenure.
GSK continues to invest heavily in its late-stage pipeline, digital-enabled R&D, and partnerships aimed at addressing some of the world’s most pressing health challenges.
About GSK
GSK is a global biopharma company focused on preventing and treating disease through innovative medicines and vaccines, with a purpose to unite science, technology, and talent to get ahead of disease together.
By